Infectious disorders drug targets · 2026
Rheumatoid Factor and Anti-CCP Titers in COVID-19.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Abakar Mudathir Abdelshafea Abdelkareem, Awadab Mohamed Ibrahim, Elaraki Zohair Khalid Ibrahim, Osman Mohammed Elsheikh, Ibrahim-Holi Mohamed Ahmed, Ahmed-Abakur Eltayib Hassan, Alnour Tarig M S
Аннотация
INTRODUCTION: The mechanisms of Coronavirus Disease 2019 (COVID-19) remain not fully elucidated. The present study aimed to trace the presence of autoantibodies among COVID-19 patients and to determine the association between COVID-19 and these antibodies.
METHODS: This study is a cross-sectional, hospital-based study involving 90 participants, who were arranged into three groups: the COVID-19 group, the rheumatoid arthritis group, and the control group. The study population was tested for serum concentration of rheumatoid factor and anti-CCP antibodies.
RESULTS: The results showed significant elevations in serum levels of rheumatoid factor (p < 0.000) and anti-CCP (p < 0.000) among the rheumatoid arthritis group. Similar findings of a significant increase in rheumatoid factor (p < 0.000) were observed among the COVID-19 group compared to the control group, while an insignificant increase (p = 0.605) was reported between the Anti-CCP and COVID-19 groups.
DISCUSSION: The present study revealed a significant increase in rheumatoid factors among the COVID-19 group compared to the healthy control group. These results suggested that COVID-19 contributes to the development of autoantibodies, which might play a critical role in the pathogenesis of COVID-19.
CONCLUSION: These findings suggest that the rheumatoid factor plays a crucial role in the pathogenesis of COVID-19 infection.
METHODS: This study is a cross-sectional, hospital-based study involving 90 participants, who were arranged into three groups: the COVID-19 group, the rheumatoid arthritis group, and the control group. The study population was tested for serum concentration of rheumatoid factor and anti-CCP antibodies.
RESULTS: The results showed significant elevations in serum levels of rheumatoid factor (p < 0.000) and anti-CCP (p < 0.000) among the rheumatoid arthritis group. Similar findings of a significant increase in rheumatoid factor (p < 0.000) were observed among the COVID-19 group compared to the control group, while an insignificant increase (p = 0.605) was reported between the Anti-CCP and COVID-19 groups.
DISCUSSION: The present study revealed a significant increase in rheumatoid factors among the COVID-19 group compared to the healthy control group. These results suggested that COVID-19 contributes to the development of autoantibodies, which might play a critical role in the pathogenesis of COVID-19.
CONCLUSION: These findings suggest that the rheumatoid factor plays a crucial role in the pathogenesis of COVID-19 infection.